PCSK9 and cardiovascular disorder: As expected, PCSK9 “genetic inhibition” may target aging‐associated diseases through its association with lifelong exposure to low LDL cholesterol levels and associated reduction in the risk of cardiovascular diseases (Figure 4c and Table S13).